Stimcell Energetics Inc. is a biotech company focused on the discovery, development, and commercialization of therapeutic and non‑therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications such as aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function. The company’s primary focus is the continued research and development of its eBalance® Technology and the eBalance® Home System. eBalance® Technology uses microcurrent electrical therapy to deliver subsensory currents that aim to support wellness and provide temporary pain relief, including relief of sore‑aching muscles in the shoulder, waist, back, neck, upper and lower extremities due to strain from exercise or normal household work. The technology underlies both the eBalance® Pro System, intended for use by healthcare professionals in clinical settings, and the eBalance® Home System, designed for direct patient use at home without a prescription.

Stimcell Energetics Inc. generates revenue mainly from the sale of its eBalance® Home and Pro Systems to medical practitioners and consumers. The company also earns income from licensing fees and recurring monthly payments under distribution agreements, exemplified by its prior worldwide distribution agreement with Live Current Media, Inc., which included an initial 1-time fee of $250,000, a minimum order of 2,000 devices, a fixed license fee of CAD$2,400 per device, and a monthly recurring fee per device equal to 50% of the regular monthly home‑use fee. Additional revenue streams have included the sale of eBalance® treatment packages through online channels and partnerships aimed at product redesign, such as the collaboration with ADM Tronics Unlimited, Inc. to create a compact, affordable consumer unit with diagnostic features. Due to the suspension of its Health Canada Class II Medical Device Licenses in June 2023, the company’s revenue‑generating activities related to device sales and recurring treatment packages were halted, although it continues to pursue opportunities to restore those licenses and secure financing for future commercialization.

Stimcell Energetics Inc. operates within the medical device industry, specifically in the niche of microcurrent therapy for diabetes management and general wellness. The broader diabetes care market is substantial, with the International Diabetes Federation reporting approximately 537 million adults living with diabetes in 2021 and projecting growth to 783 million by 2045, creating a large potential customer base for complementary therapies. Indirect competitors include pharmaceutical manufacturers of diabetes medications, makers of glucose monitoring devices, and other microcurrent therapy companies such as BodiHealth Systems and Electromedical Products International, Inc., which markets the Alpha‑Stim® PPM device. The company’s competitive advantages lie in its proprietary eBalance® Technology, which is grounded in bioelectric signal science and epigenetic modulation, the prior Health Canada Class II certifications for its eBalance® Home and Pro Systems, and clinical trial data showing improvements in fasting blood glucose, plasma insulin, HbA1c, blood pressure, and pain reduction. However, limited funding has constrained the ability to maintain regulatory certifications and to advance toward FDA 510(k) clearance, affecting its market position relative to larger, well‑capitalized competitors.

The company serves healthcare professionals, including clinics and practitioners, through its eBalance® Pro System, which is configured for clinical use with hand bars, foot plates, and pen probes for localized treatment. It also serves individual consumers through its eBalance® Home System, designed for home use without a prescription and controlled by a console that administers pre‑programmed microcurrent algorithms. Specific customer names disclosed in the filing include Live Current Media, Inc., which acted as a worldwide distributor under an exclusive agreement, and ADM Tronics Unlimited, Inc., a partner engaged to redesign the eBalance® Home device into a more compact, affordable unit. In addition, the company has sold eBalance® treatment packages directly to patients via online sales, generating recurring monthly revenue from those users. While revenue‑generating activities have been suspended pending the restoration of regulatory licenses, the underlying customer base remains comprised of medical providers seeking adjunctive diabetes therapies and consumers interested in home‑based wellness and pain‑management devices. The company has no employees other than its executive officers, who provide services as independent consultants, and contracts for medical and technical staff on an as‑needed basis to support clinical observations and trials.